Subcutaneous Sarilumab vs Placebo in Hospitalized Patients With Respiratory Distress Caused by COVID 19

Exclusion Criteria

• •1. The subject or Legally Authorized Representative is unable to provide consent in person or by phone.
• •2. The subject is participating in any other clinical trial for treatment of COVID 19 or any other treatment related clinical trial for a concurrent disease. No plans for additional COVID trials.
• •3. The subject does not meet criteria for moderate to severe respiratory distress.
• •4. The presence of any of the following lab abnormalities. ANC \<2000/mm3, Platelet count \<50,000/mm3, ALT/AST \>6x ULN
• •5. Prior utilization of any IL-6 inhibitors or receptor antagonists at any time in patient's life, JAK inhibitors, DMARDS(Except Hydroxychloroquine), long term, chronic steroid use (more than 6 months) or mTOR inhibitors.
• •6. The subject has history of organ or bone marrow transplant.
• •7. History of active or incompletely treated Tuberculosis (TB).